Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3)-Reference-Cited by-同舟云学术

Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3)

Published:2020-02 Issue:2 Volume:106 Page:255-260
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Trifiletti Daniel M.,Ballman Karla V.,Brown Paul D.,Anderson S. Keith,Carrero Xiomara W.,Cerhan Jane H.,Whitton Anthony C.,Greenspoon Jeffrey,Parney Ian F.,Laack Nadia N.,Ashman Jonathan B.,Bahary Jean-Paul,Hadjipanayis Costas G.,Urbanic James J.,Barker Fred G.,Farace Elana,Khuntia Deepak,Giannini Caterina,Buckner Jan C.,Galanis Evanthia,Roberge David

Funder

National Cancer Institute

National Institutes of Health

Alliance for Clinical Trials in Oncology

CCTG

NRG

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference17 articles.

1. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017;18(8):1049-1060.